Zimmer Biomet, US98956P1021

Zimmer Biomet stock holds gains after a solid Q2 beat

Published on 08/19/2026 at 12:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Zimmer Biomet stock held near $99 after Q2 EPS of $2.07 topped estimates by $0.06 and revenue rose 4.8% year over year.

Börsen-Editorialfoto vom Trading-Floor mit Charts der Medizintechnik-Branche
Zimmer Biomet US98956P1021 zeigt Börsen-Editorial vom Trading-Floor mit Charts der Medizintechnik-Branche auf Bildschirmen, Illustration mit AI erstellt.

Zimmer Biomet (ISIN US98956P1021) stock traded at $99.31 on August 18, 2026, after a second-quarter report that showed $2.07 in adjusted EPS and revenue growth of 4.8% from a year earlier.

The latest read-through matters because the company beat the $2.01 consensus by $0.06, and market data put the stock at a $18.94 billion market cap with a 24.16 P/E ratio and a 3.20 PEG ratio on August 19, 2026.

Q2 numbers set the tone

On August 5, 2026, the company reported quarterly earnings that also showed the medical equipment provider's revenue up 4.8% year over year, while the same day market snapshot at $100.08 implied a 1.92% gain in regular trading.

That combination of a 2.99% earnings surprise and a market value close to $19 billion leaves the stock trading in a relatively tight range, with the quote pages in this call clustering around the high-$90s to $100 area.

Consensus still points to hold

MarketBeat data shows a consensus rating of Hold and an average price target of $104.42, which leaves only a modest gap from the latest quoted levels.

For investors, the cleaner comparison is the gap between the August 5 EPS beat of $0.06 and the market's muted reaction, not a dramatic rerating.

Rosa remains the core product

Zimmer Biomet's robotic surgery platform Rosa is still the company's most visible growth product, anchored in orthopedics and used to support procedures across knee and shoulder surgery.

The product mix matters because Zimmer Biomet's earnings profile is being driven more by execution in the core implant and robotics franchise than by any single short-term headline.

Stock level to watch

Zimmer Biomet shares were quoted at $99.31 on August 18, 2026, with another market snapshot at $100.08 on August 19, 2026, keeping the stock close to the $100 mark as investors weigh the $104.42 consensus target.

More on Zimmer Biomet stock

Company: Zimmer Biomet Holdings, Inc.
ISIN: US98956P1021
Ticker: ZBH
Exchange: NYSE
Sector / Industry: Health Care / Medical Devices
Index membership: S&P 500
Market cap: $18.94 billion
Next earnings date: September 30, 2026

Disclaimer...

en | US98956P1021 | ZIMMER BIOMET | boerse | 69969456 | bgmi